<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714776</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 757456-CS2</org_study_id>
    <nct_id>NCT03714776</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a Phase 2, double-blind, randomized, placebo-controlled study of IONIS-AGT-LRx
      conducted in mild hypertensive subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized in a 2:1 ratio to receive a once-weekly subcutaneous treatment
      and an additional loading dose on Study Day 3 with either IONIS-AGT-LRx or placebo for 6
      weeks.

      All subjects will complete a 13-week Post-Treatment Period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Actual">November 13, 2019</completion_date>
  <primary_completion_date type="Actual">November 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in plasma angiotensinogen from Baseline to Study Day 43 (Week 7) compared to placebo</measure>
    <time_frame>Week 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on in-clinic SBP from Baseline to each scheduled, post-Baseline visit</measure>
    <time_frame>Study Days 1, 3, 8, 15, 22, 29, 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in plasma angiotensinogen from Baseline to each scheduled, post-baseline visit</measure>
    <time_frame>Study Days 1, 3, 8, 15, 22, 29, 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Mild Hypertension</condition>
  <arm_group>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS-AGT-LRx injected subcutaneously once-weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching solution injected subcutaneously once-weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-AGT-LRx</intervention_name>
    <description>IONIS-AGT-LRx injected subcutaneously once-weekly</description>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching solution injected subcutaneously once-weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Females must be non-pregnant and non-lactating, and either surgically sterile or
             post-menopausal.

          2. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with
             a woman of child-bearing potential, the subject or the subject's non-pregnant female
             partner must be using a highly effective contraceptive method

          3. Body Mass Index (BMI) â‰¤ 35.0 kg/m2

          4. Subject must have been diagnosed with essential hypertension for a minimum of 3 months
             prior to screening

          5. At Screening, on a stable regimen of antihypertensive medications for at least 1 month
             prior to screening

          6. Agree to conduct at home BP and HR monitoring three times weekly and document the
             average of the triplicate measurements assessed on a day in the patient diary

        Exclusion Criteria

          1. Clinically-significant (CS) abnormalities in medical history, screening laboratory
             results, physical or physical examination that would render a subject unsuitable for
             inclusion

          2. The use of the following at time of screening and during the course of the study:

               1. Other medications for the treatment of hypertension (e.g., clonidine, guanfacine,
                  guanabenz, alpha-methyldopa, hydralazine, minoxidil, diazoxide, renin inhibitors)

               2. Medications that also may cause hyperkalemia (e.g., cyclosporine or tacrolimus,
                  pentamidine, trimethoprim-sulfamethoxazole, all heparins)

               3. Oral or subcutaneous anticoagulants (e.g., warfarin, rivaroxaban, apixaban,
                  heparin, lovenox)

               4. Organic nitrate preparations (e.g., nitroglycerin, isosorbide mononitrate,
                  isosorbide dinitrate, or pentaerythritol)

               5. Sildenafil, tadalafil, vardenafil

          3. Unwilling to discontinue antihypertensive mediations during WO and Treatment Period of
             study

          4. Subject has a history of secondary hypertension

          5. Unstable/underlying cardiovascular disease defined as:

               1. Any history of congestive heart failure (NYHA class II-IV)

               2. Any history of previous stroke, transient ischemic attack, unstable or stable
                  angina pectoris, or myocardial infarction prior to screening

               3. a history or evidence of long QT syndrome

               4. Any clinically-significant active atrial or ventricular arrhythmias

               5. Any history of coronary bypass or percutaneous coronary intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research - Lyndhurst</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC - Northwest Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Clinical Research LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Hypertensive</keyword>
  <keyword>AGT</keyword>
  <keyword>Angiotensinogen</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>High Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

